Idorsia Ltd (IDIA.SW) SIX

4.43

-0.135(-2.96%)

Updated at December 23 05:31PM

Currency In CHF

Idorsia Ltd

Address

Hegenheimermattweg 91

Allschwil, 4123

Switzerland

Phone

41 58 844 10 10

Sector

Healthcare

Industry

Biotechnology

Employees

636

First IPO Date

June 16, 2017

Key Executives

NameTitlePayYear Born
Srishti GuptaCEO & Executive Director50,8361976
André C. MullerAdvisor1.01M1963
Andrew JonesSenior VP, Head of Corporate Communications & Investor Relations01975
Arno GroenewoudExecutive VP & CFO01971
Martine ClozelExecutive VP, Chief Scientific Officer & Head of Research01955
Alberto GimonaExecutive VP and Head of Global Clinical Development & Medical Affairs01960
Alexander KhatuntsevSenior VP & Head of Global Human Resources01978
Christoph BossSenior VP & Head of Drug Discovery Chemistry01968
Julien GanderExecutive Vice President, Chief Legal & Corporate Development Officer and Company Secretary01979
Olivier LambertSenior VP & Head of Technical Operations01966

Description

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.